Integrating Treatment in Eating Disorders

Integrating Treatment in Eating Disorders

While anorexia nervosa was the first eating disorder to be recognized through the 19th century reports of Gull (1874) and Las?que (1873), bulimia nervosa and the less well-defined eating disorder not otherwise specified (EDNOS) syndromes are more common. Bulimia nervosa was first described by Russell in 1979 and was introduced into the American Psychiatric Association classification scheme in the 1980 DSM-III, where it was termed bulimia. In clinical samples, however, people with EDNOS may comprise one-third to one-half of patients seen (Hall and Hay, 1991; Herzog et al., 1993). The EDNOS syndromes include people who fall below the diagnostic criteria for bulimia nervosa or anorexia nervosa. Binge-eating disorder is a third classification of eating disorder and is listed as the sixth example of an EDNOS syndrome in the DSM-IV as "recurrent episodes of binge eating in the absence of the regular use of inappropriate compensatory behaviors characteristic of Bulimia Nervosa" (APA, 1994). It is also in Appendix B with suggested criteria as a diagnostic group for further study.

With an estimated point prevalence of 0.5% in young women, anorexia nervosa is not a common condition (Aalto-Setala et al., 2001). A systematic review of 12 cumulative incidence studies reported an estimated mean annual incidence in the general population of 18.46 per 100,000 (SD=21.01) in women and 2.25 per 100,000 (SD=2.63) a year in men (Pawluck and Gorey, 1998). There is limited evidence for changes in the overall incidence of anorexia nervosa over time, although the authors reported a significant increase in its incidence in young women from 1950 to 1992.

In contrast, bulimia nervosa is more common, with estimated incidence of 28.8 (SD=29.7) in women and 0.8 (SD=0.0) in men per 100,000 per year (Pawluck and Gorey, 1998). The general population lifetime prevalence of bulimia nervosa is around 1%. Point prevalence in young women from combined estimates has also remained around 1% (e.g., Bushnell et al., 1990) since the 1980s, when there was an increase in clinical incidence following its recognition as a disorder (e.g., Hall and Hay, 1991). Finally, the prevalence of EDNOS syndromes is estimated between 2% and 5% in young women (e.g., Hay, 1998).

Overview of Treatments

Historically, the treatment of people with eating disorders has moved from a focus on medically supervised physical weight restoration, as described by Gull (1874), through the introduction of the first variants of psychodynamic psychotherapy in the 20th century and, later, the development of specific focus symptom-based treatments, such as cognitive-behavioral therapy (CBT).

Alongside these developments in psychotherapy has been the use of pharmacological therapies, as they became available to the wider psychiatric clinical services. A number of the older tricyclic antidepressants, typical neuroleptic medications and, more recently, selective serotonin reuptake inhibitors have been trialed in eating disorders. A range of other medications have been also used in eating disorders to specifically treat comorbidity, such as depression or severe anxiety, and medical complications, such as severe constipation, delayed gastric emptying and osteopenia found in anorexia nervosa. An authoritative and comprehensive overview of these developments is found in Garner and Garfinkel (1997).

Anorexia Nervosa

With regard to integrating treatments, pharmacotherapy is used most often in patients with anorexia nervosa as an adjunct to inpatient weight-restoration programs or to outpatient psychotherapy and weight-maintenance programs. A systematic review presented to the ninth Cochrane Colloquium identified 19 randomized, controlled trials (Hay et al., 2001). Trials were identified by the author from a search of six databases and a hand search of The International Journal of Eating Disorders. Most trials had fewer than 50 subjects and were negative. Space precludes a discussion of all these trials; this paper focuses on those that have evaluated antidepressants (Table 1).

The double-blind, randomized, controlled trial by Kaye et al. (2001) is notable for its long duration and placebo-controlled evaluation of fluoxetine (Prozac), previously found to be effective in bulimia nervosa (Bacaltchuk et al., 2000). Kaye et al. studied 35 subjects with restricting and restricting-purging types of anorexia nervosa recruited during an inpatient program and followed them for one year. Weight gain and psychological measures (core eating disorder symptoms, depression, anxiety, obsessions and compulsions) improved only in the 10 patients who remained on fluoxetine treatment. Dropouts were much higher in the placebo group (84% versus 37%). The high refusal rate and small numbers limited conclusions from the study. The authors postulated that there may be a relative serotonin "resistance" due to a compromised release of serotonin from presynaptic storage in underweight individuals with anorexia nervosa. The authors argued that this may reverse with weight gain and may explain the greater efficacy of SSRIs in normal-weight people with eating disorders.

Therefore, there is insufficient evidence at this stage to support antidepressant therapy in combination with psychotherapies and various nutritional rehabilitation programs alone. As patients with anorexia nervosa are in a compromised physical state due to the effects of starvation, low dosage and caution is recommended in the use of most psychotropics and other agents, including antidepressants, for which there is limited evidence of efficacy (Treasure and Schmidt, 2001).

Cyproheptadine, a serotonin and histamine antagonist, has also been the subject of randomized, controlled trials for anorexia nervosa treatment, with one relatively large study (n=72, Halmi et al., 1986) supportive and another (n=105, Goldberg et al., 1980) not so. As with antidepressants, there is insufficient evidence as yet of its efficacy.


Loading comments...
Please Wait 20 seconds or click here to close